AstraZeneca PLC (AZNCF)
| Previous close | 0.00 |
| Open | 169.00 |
| Bid | 158.45 x 47300 |
| Ask | 164.00 x 38500 |
| Day's range | 166.00 - 169.00 |
| 52-week range | 118.16 - 175.00 |
| Volume | |
| Avg. volume | 1,480 |
| Market cap | 258.398B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 38.89 |
| EPS (TTM) | 4.12 |
| Earnings date | 12 Nov 2024 |
| Forward dividend & yield | 2.98 (1.86%) |
| Ex-dividend date | 08 Aug 2024 |
| 1y target est | N/A |
Insider MonkeyAstraZeneca PLC (AZN): Short Seller Sentiment For This Big-Name Stock is Bullish
We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other big name stocks. In early April 2024, Goldman Sachs Inc.’s data revealed that short selling on individual US-listed stocks […]
ZacksRelay Stock Soars on Upbeat Data From Breast Cancer Study
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
PR NewswireSOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ to 20 locations worldwide over the next 12 months.
